• The Green Organic Dutchman participated in the renowned Cannabis Investor Conference held by New West Partners
• TGOD received a 100 percent organic rating from Toronto-based Corporate Knightsmagazine
• The company endeavors to become a global leader in the delivery of high-quality, sustainable cannabis

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a company dedicated to producing organic cannabis using craft farming techniques, was one of the presenters at the Cannabis Investor Conference held by New West Partners on August 22, 2019, in San Francisco, California (http://ibn.fm/A4qjv). Based in Hamilton, Ontario, The Green Organic Dutchman is committed to become a global leader in the delivery of premium-quality cannabis in compliance with the provisions of ACMPR and the Controlled Drugs and Substances Act (Canada).

Recently, TGOD received a 100 percent organic rating from Toronto-based Corporate Knights magazine (http://ibn.fm/B0fNJ). The company is one of the few in Canada licensed to cultivate organic cannabis. The Green Organic Dutchman is a pioneer in shifting from indoor farming to greenhouse cultivation, making use of solar energy and cutting electricity costs by up to 90 percent. Companies leading this effort are using glass-roofed greenhouses equipped with the latest high-tech equipment to produce ‘sun-grown’ organic cannabis (http://ibn.fm/r7uCv).

Canada has become a magnet for cannabis investors, with more than $1.3 billion raised by Canadian companies to date. The country has 58 licensed producers servicing a population of 36 million, but it only boasts two organic producers. Canada’s legal cannabis sector has been busy trying to meet heavy demand since legalization in October 2018, so companies have not given much thought into how the industry can track, disclose and better the sector’s ESG (environmental, social and governance) factors. However, where many companies refrain from taking on the social responsibility that should come from cultivation, TGOD rose to the occasion.

The Green Organic Dutchman has positioned itself as one of the industry’s most cost-efficient companies while still delivering high-quality organic cannabis used to improve the lives of its customers. TGOD holds licenses and is located in both Ontario and Quebec, which together have a population of 22 million Canadian residents. The company caters to both recreational users and Canada’s medical market.

TGOD has applied a different approach to running a sustainable and successful cannabis company. That approach includes:

• Following the principle of “grow to scale” and concentrating on growing organic produce;
• Controlling logistical and infrastructure departments;
• Teaming up with the world’s second-largest power-management company, Eaton;
• Teaming up with Canada’s second-largest construction management company, Ledcor; and
• Creating a world-class CPG senior management team.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Lexaria Bioscience recently announced its DehydraTECH(TM) patent for pharmaceutical applications of cannabinoids to treat certain disease conditions
• Lexaria Bioscience’s patented DehydraTECH drug delivery platform can be used to deliver nicotine, cannabinoids and many other useful substances
• The company has roughly 60 patents pending in countries around the world for its DehydraTECH drug delivery platform

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is at the forefront of the development of useful biotechnology products and has played a pivotal role in developing a way to deliver substances to the brain via non-inhalation methods through the development of a novel drug delivery platform.

The DehydraTECH drug delivery platform was developed by Lexaria Bioscience Corp. and has already received patents in both the United States and Australia, most recently for pharmaceutical applications of cannabinoids to treat certain disease conditions (http://ibn.fm/gRhN0). In addition, patents are also pending in over 40 countries around the world. The delivery method can be used in a variety of forms, including in edible foods and beverages, and the technology has several benefits and applications for the pharmaceutical industry.

This innovative technology can be used to safely deliver nicotine and a range of other substances, including cannabidiol, to the body via ingestion rather than inhalation. It has been recognized that inhalation is dangerous and associated with other medical problems. Thus, finding an alternative means for the effective and safe delivery of substances which have traditionally been inhaled is advantageous. A total of nine corporations have signed 11 definitive contracts to use Lexaria’s revolutionary DehydraTECH drug delivery platform, and its client base continues to expand exponentially.

It is clearly a benefit to find and use edible or drinkable products as a way of delivering substances to the bloodstream. It is also beneficial that the delivery system works in beverages, for individuals who may be having trouble eating solid foods. Consequently, new patent applications related to the recent innovations have been filed by Lexaria (http://ibn.fm/aXdDw).

This patented delivery system works in such a way that the required substance can be absorbed by the gastrointestinal system. This is an important development, since previous edible products containing substances such as nicotine were found to be poorly absorbed from the gut, which meant that they were not very effective for the purposes of delivering the nicotine in a safe manner. In addition, no sugar additives are needed, since this product blocks any unpleasant or bitter taste. This is a big benefit, because it means that unhealthy taste-enhancing substances do not need to be added to products to make them palatable. The DehydraTECH drug delivery platform also enables the substances to bypass first phase liver metabolism.

Lexaria’s DehydraTECH drug delivery platform has been shown to rapidly deliver nicotine and cannabidiol to the brain. In general, the ingestion of nicotine and cannabinoids in this way means that far more of the substance is absorbed than through other means of edible ingestion, which is a distinct advantage. Lexaria, through its relationship with Canada’s National Research Council (“NRC”), also continues to investigate what interactions take place at the molecular level between nicotine polacrilex formulations and DehydraTECH’s methodology in order to continually improve on DehydraTECH and expand scientific understanding of its processes.

The platform does work very well in delivering non-psychoactive cannabinoids, which have been recognized as beneficial in treating many ailments (http://ibn.fm/dr6Py). In a human clinical test, DehydraTECH achieved a 319 percent higher CBD blood concentration compared with other systems within 30 minutes of ingestion.

Cannabidiol is a helpful substance that has potential for the treatment of many medical conditions, and a quick uptake of the substance is important in people who desire rapid relief of unpleasant symptoms such as nausea and pain. The CBD acts on special receptors in the brain which causes changes in how the nervous system functions (http://ibn.fm/ZBpdf).

There is scientific evidence to substantiate many of the health benefits of CBD. Besides helping to alleviate symptoms of nausea, CBD has been found to work well in patients who have seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome, which are difficult to treat by conventional means. The cannabinoid also helps with pain and even anxiety.

Inhalation may be a quicker route for getting cannabinoids and certain other substances into the brain, but it is harmful to the body, which is why this new delivery technology is preferable. Lexaria Bioscience Corp. has 16 patents granted for DehydraTECH for the safe, rapid and effective delivery of cannabidiol.

A further advantage of the platform is that several other fat-soluble substances can be delivered using the DehydraTECH drug delivery platform. For instance, the DehydraTECH delivery system can be used for the rapid delivery and gastrointestinal uptake of substances including fat-soluble vitamins, such as vitamin A and E, and non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid and ibuprofen. There is also potential for the use of DehydraTECH to deliver drugs that can help with nervous system disorders such as Alzheimer’s disease. This is helpful, since the blood-brain barrier has sometimes been an obstacle for the delivery of drugs to the brain. Lexaria attributes its recent commercial success largely to its rapidly expanding body of scientific results that prove the superior capabilities of its patented technologies.

For more information, visit the company’s website at www.LexariaBioscience.com

• Wildflower Brands recently completed its acquisition of City Cannabis Corp. in a deal that includes four operating retail cannabis stores and renovations to additional locations
• Wildflower holds 14 licenses for cannabis cultivation, manufacturing, distribution and retail in California, the world’s largest cannabis market
• Expansion plans into Europe’s CBD market are underway via an agreement with Poland-based wellness distribution company Two Towers

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) continues its expansion of retail, online sales and production capacity in both Canada and the United States, building on its strategic goal of becoming a global wellness leader. Its recent acquisition of City Cannabis Corp., which currently serves the Vancouver, British Columbia, cannabis market, included four retail cannabis stores and the renovation of additional retail locations.

The purchase of City Cannabis Corp. expands Wildflower’s reach and strengthens the company’s status as a leading brand-focused industry leader in the cannabis and CBD industry (http://ibn.fm/n0174). City Cannabis has been turning a profit in dispensary operations since Vancouver started licensing cannabis retailers, posting revenues of $1.8 million for the quarter ended March 31, 2019.

“City Cannabis is no doubt the fastest growing multiple location cannabis retailer in British Columbia,” Wildflower CEO William MacLean said in a news release. “The team has demonstrated their ability to find the best locations, but more importantly, the knowledge and ability to work with regulators at all levels has meant success in licensing that is unmatched.”

Wildflower also expanded its retail presence in the U.S. with the launch of its wellness products in more than 260 Dillard’s department stores. The initial purchase order from Dillard’s is significant, MacLean said in a news release, since it enables Wildflower to enter new markets in several U.S. states (http://ibn.fm/3N99A).

“Launching into Dillard’s will double the number of retail locations we are in overnight. Our strategy is to build off our established brand equity in these key markets that can catapult us into becoming a household name,” MacLead continued. “Dillard’s has the respect and reputation as a retailer that fits in with our loyal following. I am looking forward to bringing the wellness and health benefits of CBD through Wildflower’s products to Dillard’s clientele.”

Wildflower’s CBD-infused products can also be found at wellness guru Joel Warren’s ‘The Salon Project’ at Saks Fifth Avenue in New York City (http://ibn.fm/5FX7d). Warren is a celebrity beauty and wellness icon who has been a leader in the hair care industry for more than 30 years. The Salon Project at Saks Fifth Avenue features a full salon and lounge space, a VIP treatment room and a curated “shop-in-shop” CBD beauty corner.

The lucrative U.S. CBD market is estimated to grow to $22 billion by 2022 (http://ibn.fm/mLqGF) and $75 billion by 2030 (http://ibn.fm/H4H7q). With the inclusion of Dillard’s stores, Wildflower products are now in distribution in 600 locations across America.

“In this soon-to-explode global CBD marketplace, those with the most recognized brands that have developed a loyal customer base will emerge as the world leaders,” MacLean said. “Our strategy is to build off our established brand equity in these key markets and partner with brands that can catapult us into becoming a household name.”

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

Pure-play cannabis-infused beverage manufacturer Tinley Beverage Company (CSE: TNY) (OTCQX: TNYBF) recently announced that it has completed the buildout of its permanent bottling facility in Long Beach, California. The company is currently producing its five alcohol-inspired cannabis beverages via a temporary manufacturer, making it one of the only publicly traded companies and the only pure play that now has cannabis beverages in the market.

Tinley’s 20,000-square-foot, state-of-the-art-facility is purpose-built for cannabis beverage production, and the company reported that its line is capable of producing at least one million bottles per month, with a space plan for two additional lines that would accommodate additional formats such as shot bottles and cans. The company’s products currently retail for between $6 and $45 per bottle, suggesting revenue capacity that exceeds $100 million, even if not fully utilized.

Leveraging the experience of its president, Rick Gillis, who was previously the president of the second-largest alcohol distributor in the western U.S. (Young’s Market Company, which generates $3 billion annually in sales), Tinley is offering a suite of beverage-specific DSD services to existing California cannabis distributors. This enables such distributors to offer the additional merchandising and other services that beverage DSD distributors offer that typically aren’t required for other consumer product categories. This enables existing cannabis distributors to offer these additional services without having to invest in a reconfiguration of their sales forces or fleets for beverages.

Another heavy-hitter on Tinley’s team is Ted Zittell, who was previously a president of Cott, which at the time was the third-largest beverage company in the world after Coke and Pepsi. Cott’s core business was offering co-packing, branding and merchandising services to help consumer and lifestyle brands extend their offerings into the cola business. Tinley’s team has done this for 100+ such brands and intends to use the same process for helping mainstream beverage and other consumer brands create cannabis beverages. This service effectively positions Tinley to provide a full-service solution for any such companies that want to create offerings in the cannabis beverage industry.

Completion of Tinley’s production site comes on the heels of the company providing the keynote presentation at the first-ever Cannabis Drinks Expo, which recently took place in San Francisco, California. The expo was organized by the internationally recognized Beverage Trade Network, representing the increasingly mainstream standing of the burgeoning category.

Tinley discussed how the science of infusing cannabis into beverages is no longer a challenge, thanks to the multitude of companies that now offer these solutions on competitive terms. These solutions enable beverage companies to provide consumers with an enjoyable full-flower effect, comparable to vaping, with rapid onset times and no trace of cannabis taste.

With science no longer a challenge, Tinley indicated that the next hurdle is infrastructure. Consumers of mainstream alcohol and health beverages are accustomed to lower prices and elaborate drink shelf merchandising, largely as a result of the extensive beverage infrastructure that has been installed across the country over the past 100 years. Cannabis beverages remain more expensive than comparable single-serve alcohol products like beer and wine coolers, largely because the country’s beverage infrastructure isn’t cannabis-licensed. Further, dispensaries don’t typically give premium shelf space to beverages, given the nascency of the category.

Overcoming the price and merchandising hurdles requires scaled bottling facilities, as well as the addition of the type of merchandising services that are typically provided by traditional beverage DSD distributors. The completion of Tinley’s large-scale, purpose-built bottling and DSD facility solves this problem.

With science and infrastructure now “solved,” Tinley expects 2019 to be a “breakout” year for the cannabis-infused beverage industry. MolsonCoors CEO Mark R. Hunter was quoted as saying that he felt cannabis beverage could grow to 20-30 percent of the cannabis industry. There are a lot of ‘ifs’ to make this happen, but, if science and infrastructure are indeed fully solved as they now appear to be, this large market share might not be that much of a stretch as mainstream consumers seek to enter cannabis without having to smoke.

Hunter’s forecast suggests a $1 billion beverage category growing to $3-5 billion in California alone as the state’s cannabis industry grows (and 10-times that as cannabis becomes legal across the country). At minimum, beverage should hit the 11 percent share that mainstream beverages have in retail stores – the largest single category in grocery stores – which suggests a $300 million to $3 billion opportunity in California. Of course, it requires availability in lounges and other on-premise locations to truly soar (in addition to the at-home channels that are currently available), but these kinds of lounges are rapidly opening up in California and Nevada, and no doubt other states and Canada will follow. On that note, Tinley is well on its way to opening up shop in Canada, where Cott is headquartered, which should attract a whole new wave of visibility and opportunity.

The company indicated that it is committed to remaining a pure-play cannabis beverage company so that it remains an effective vehicle for public market investors looking to participate in this fast-growing subcategory within the cannabis industry. As a pure play, it is unaffected by changes in cultivation, extraction, edibles or other product categories, so its returns should be reflective of the growth that’s expected from beverages. The company’s investors will benefit from economics not only from the company’s own Tinley-branded products, which have received spectacular reviews and awards in their own right, but also from a diversified (and presumably large) lineup of beverages from the company’s co-packing clients.

For more information, visit the company’s website at www.DrinkTinley.com

• VPR Brands is set to benefit from the approval of medical marijuana in South Asian markets
• The Thai marijuana industry is expected to reach $661 million by 2024
• VPRB announced growth of $1.58 million for Q2 2019, marking a 31 percent increase over last year

VPR Brands LP (OTCQB: VPRB), a technology holding company whose assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and electronic cigarette products and components, is positioned to benefit as the Southeast Asian medical market could soon start using medical marijuana for the treatment of its patients. This news was announced by Thailand Public Health Minister Anutin Charnvirakul, who is also the deputy prime minister of Thailand (http://ibn.fm/mQJT3). This is the first time that Thai state hospitals will be administering cannabis oils to patients since the country passed legislation allowing such treatment.

“This is the outcome of legalizing medical cannabis,” Charnvirakul stated in a press conference. “There is no hidden agenda. We only want to support every patient.” The Government Pharmaceutical Organization (GPO) delivered the initial shipment to the public health ministry to distribute to hospitals for about 4,000 registered patients; additional oils will be distributed in coming weeks.

In December 2018, Thailand became the first Southeast Asian nation to legalize the use of marijuana for medical purposes (http://ibn.fm/uKqTf). Under this law, the Thai government will be regulating the production, processing and sale of medical marijuana products. Prohibition Partners, a marijuana research firm, forecast that the marijuana industry in Thailand could be worth around $661 million by 2024 (http://ibn.fm/48D8f), and only licensed companies will be granted access to activities related to the new medical marijuana industry.

In addition to its U.S. patents, VPR Brands has Chinese-issued patents for atomization-related products. These patents include technology for medical-marijuana vaporizers and e-cigarette products and components. Since the company is already engaged in dealing with medical-marijuana products in the Chinese arena, the progress of medical marijuana in Thailand will further accelerate the VPR Brands’ expansion plans into the South Asian markets. Industry experts recognized VPR Brands specifically as one such company to be “thrilled that the Asian medical marijuana market could soon open up.”

VPR Brands’ has an extensive line of products that include accessories and vaporizers for cannabidiol (CBD), cannabis extracts and concentrates. The company also develops products for the vaping market, including e-vaporizers and e-liquids, and has alliances with top global brands in the vaping industry. The company’s growth strategy centers on adding more products while increasing production and thereby increasing sales.

VPR Brands CEO Kevin Frija has more than 30 years of valuable marketing and managerial experience. Under his sound leadership, VPR Brands is maneuvering toward the cannabis industry, which has led to an upsurge in sales and profit margins.

Recently, the company announced sales of $1.58 million for the three-month period ended June 30, which marked a 31 percent increase over the same period of 2018 (http://ibn.fm/cnc3i).

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• BIGtoken is the first digital exchange of transparent and verified consumer data, providing subscribers with the ability to own and earn from their own personal data
• BIGtoken’s diverse global subscriber base is experiencing viral growth, reaching nearly 16 million users by mid-August 2019
• SRAX grew its total revenues in Q2 2019 by 53 percent as compared to Q1 2019, and it has officially changed its name as part of its new business strategy

SRAX Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management and distribution technology platform company providing marketers, content owners and consumers with the tools to unlock, amplify and maximize the value of data. Through its blockchain identification graph technology, or BIGtoken platform, SRAX has designed a consumer-powered data marketplace through which people own and sell their data, providing everyone in the internet ecosystem with the ability to be compensated for and control their own data.

Consumer data is valuable not only to the individual, but also to companies seeking to harvest insights and monetize that data into new revenue models, according to a Forbes article highlighting results of PwC’s 22nd Annual Global CEO survey (http://ibn.fm/wWULi). Data is multiplying at a mind-boggling rate, the article states, which means that companies need to unlock the full value of data while also focusing on its secure and ethical use.

Through BIGtoken, consumers are finally allowed to own and monetize their own data. Consumers decide what data is shared, who can buy it and how it’s used, while advertisers reach real, responsive audiences. Consumers finally know how their data is used and advertisers gain ethically sourced, verified consumer data for targeting.

“Through BIGtoken we put data back into the hands of consumers and through our verticals are delivering verified data to brands looking for a competitive edge,” SRAX CEO and Founder Christopher Miglino stated in a news release (http://ibn.fm/0EZhQ).

In a recent study released by the Stanford Graduate School of Business, economics professors Christopher Tonetti and Charles I. Jones found that consumers wanted to preserve private data, but would elect to sell other personal data to many different firms, capitalizing on the value inherent in sharing their data (http://ibn.fm/44Z62).

To date, SRAX has nearly 16 million BIGtoken users worldwide who have opted-in to monetize their personal data. The BIGtoken platform provides consumers, marketers and developers with a comprehensive data-management solution that leads to consumer empowerment and compensation; data verification and authentication; and open-source governance and development, as a recent article explains (http://ibn.fm/50Cl4).

SRAX has made substantial technology advancements through the SRAX IR platform and BIGtoken, Miglino stated in a news release. SRAX reported a 53 percent revenue growth from Q1 2019 to Q2, for the three months ended June 30, 2019 (http://ibn.fm/NHGDF).

“BIGtoken is the leading edge of the new data economy,” Miglino added. “Our global and diverse BIGtoken subscriber base experienced viral growth in April and reached 15.9 million users as of this week. During the third quarter, we began to monetize our BIGtoken users, as we engaged with brands and several marketing agencies.”

Miglino said that SRAX is now focused on increasing scale within certain data segments in specific countries. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. The Yash Birla Group, based in Mumbai, is one of the country’s largest conglomerates, with diversified interests in consumer and industrial products (http://ibn.fm/V5V4P).

“Through building what we predict will be one of the most valuable opt-in data sets in the world, we are well positioned to generate long-term revenue and value for shareholders,” Miglino concluded.

For more information, visit the company’s website at www.SRAX.com

• The company’s CEO discussed NTRR’s strategic acquisition of hemp retail brand Vivis and hemp cultivator J3 Holdings
• Neutra Corp. plans to finish building and lab improvements to J3 Holdings in 2019
• The company’s focus is on CBD as an option to treat types of chronic pain
• CBD sales in the U.S. are projected to exceed $20 billion by 2024

Texas-based Neutra Corp. (OTCQB: NTRR) is expanding into hemp cultivation and purified hemp extract products. Its CEO, Sydney Jim, discussed the company’s operations and objectives in an exclusive interview with NetworkNewsWire (http://ibn.fm/8n9BU). Jim, a former professional tennis player, emphasized the company’s motivation to help the next generation of athletes with pain management. During the interview, he talks about dealing with pain, not only as a former professional athlete but, on an occasion as recent as last year, when he suffered multiple severe injuries and broken bones as a result of an accident.

Jim knows the benefits of hemp-based products first-hand, and CBD may offer an option for treating different types of chronic pain. A study cited by Harvard University showed that CBD applied on the skin could help lower pain and inflammation due to arthritis (http://ibn.fm/F3emW). Other research demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain – two of the most difficult types of chronic pain to treat.

Neutra Corp.’s goal in 2019 is to become vertically involved in the hemp market, from cultivation to formulation of products and distribution for retail sales in an ever-growing market. Leading cannabis researchers BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024, forecasting a 49 percent compound annual growth rate across all distribution channels (http://ibn.fm/qKj7e).

Neutra’s interests go above and beyond profit. “Most of our focus, obviously, is in our quality and potency of our products, because there is a vast difference between very cheap products and quality products,” Jim said in the interview. It takes a lot of time to extract CBD and make sure only the best quality is made available, which is why those particular products are relatively expensive, Neutra Corp.’s CEO added.

Jim also talked about the company’s strategic acquisition of Vivis, a hemp retail brand with which the Neutra CEO has personally worked. Vivis’ extracts are certified by a third-party lab to ensure their quality. Each Vivis product comes with a certificate of analysis as proof of quality, Jim explained.

Neutra Corp. also aims to finish the building and lab improvements of hemp cultivator J3 Holdings, for which the company recently submitted a letter of intent. J3 Holdings owns a lot of land where hemp can be cultivated, as well as a warehouse – assets that are expected to increase Neutra Corp.’s value. In September, Neutra Corp. plans to “finalize the equipment going in there (J3 Holdings) and wrap the financing up to hit the ground running in 2020.”

On a final note, the company’s CEO expressed his hope of bringing Vivis and J3 together to strengthen Neutra’s market infiltration while helping it become a vertically integrated company with both a strong market presence and an established brand that’s known for the superiority of its product and its commitment to quality.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
• A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
• Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels

Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.

The company’s August 22 announcement (http://ibn.fm/Ljt7D) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within 15 minutes – sometimes as fast as two minutes in lab testing.

The rapid bio-delivery of CBD through DehydraTECH provides an avenue for safer, less conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare.

ChrgD+ has been available in a limited number of retail stores throughout the western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life without having to travel. Limited-time promotional offers and product updates are also available through the site.

Each serving of ChrgD+ weighs just two grams, making it easy for a consumer to carry multiple servings in a shirt pocket or athletic wear while on the go. The multi-spectrum oil-based powder can be poured innocuously into any hot or cold beverage, and every package contains a manufacturing batch code that makes it simple for consumers to browse lab test results for the actual potency of the package’s ingredients (which contain no THC) as part of Lexaria’s push for transparency.

DehydraTECH technology provides the added benefit of gently removing unpleasant cannabis flavors, so ChrgD+ is able to avoid the artificial flavors or sweeteners that other products may use to mask the strong flavors and aromas inherent to hemp oil.

These innovations are examples of Lexaria’s ongoing mission to enhance the “speed of action, flavor and gastro-intestinal delivery of orally-administered products,” particularly those that utilize cannabinoids, nicotine and ibuprofen.

Zenith Global’s industry analysts predict that the U.S. market for cannabis- and hemp-infused drinks will reach more than $1.4 billion by 2024, almost 15-times the 2018 level, as part of an overall trend toward life-enhancing practices that focus on alternatives to traditional medicines and recreational products, including alcoholic beverages and tobacco products (http://ibn.fm/V6ucn).

With the federal legalization of edible cannabis products only a month away in Canada, Lexaria is also preparing to roll out DehydraTECH-licensed products in collaboration with alcohol-free beer, wine and adult format beverage maker Hill Street Beverage Company Inc. (TSX.V: BEER) on a first-time business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The as-yet unnamed new brand will feature processed tetrahydrocannabinol (THC) and/or CBD powder from cannabis or its less chemically psychoactive hemp variant as part of the companies’ efforts to build production in a new market space.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• The U.S. cannabis market is racing along at a 25 percent CAGR
• Nabis Holdings recently issued a letter to shareholders
• The company has appointed an independent director

Based in Vancouver, Canada, Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) is targeting positive cash flow and strategic assets in the cannabis space, both in the United States and abroad. Nabis already has investments in Arizona, California, Michigan and Washington and is looking to expand its portfolio to include four to five more states in the next three to four months.

Nabis is headed by two industry veterans who exited another firm after receiving one of the largest takeover offers in the North American industry. The team seems set for a repeat performance in the burgeoning legal cannabis market, which is expected to grow at a CAGR of 24.9 percent from 2017 to 2025 (http://ibn.fm/EwZOw). Such growth would swell the market to around $50 billion by 2025.

Nabis is headed by Shay Shnet and Mark Krytiuk, two executives with a proven pedigree in the cannabis space. The pair are co-founders of MPX Bioceutical Corporation, which merged with iAnthus Capital Holdings Inc. (OTCQX: ITHUF) in a deal that valued MPX at C$835 million. Shnet brings 20 years of business experience to Nabis, where he serves as CEO. At MPX Bioceutical, he was vice president of operations and helped build MPX’s portfolio of international cannabis assets. Shnet is adept at sourcing unique opportunities that deal directly with the development, branding, importing, consumer packaging and distribution of a variety of product lines.

Mark Krytiuk is chairman and president of Nabis. Krytiuk garnered five years of experience as the vice president of grow operations for MPX – a position from which he oversaw the production of medical marijuana and pharma-grade products across North America. Krytiuk has been directly involved in the rapid expansion and growth of nine facilities in three different countries, including projects that involved budgets of up to $30 million.

Recently, Nabis issued a letter to shareholders providing a detailed update on the company’s progress and its outlook for the remainder of 2019 and beyond (http://ibn.fm/p9Us8). In Arizona, Nabis has entered into a definitive agreement to acquire 100 percent of the membership units of a fully integrated medical marijuana business licensed under the Arizona Medical Marijuana Act. The acquisition includes a currently operational dispensary that serves 132,000 patients in the Phoenix (Maricopa County) area. This asset has audited 2018 financials of $8.7 million in revenue with gross margins in excess of 50 percent, as well as an estimated $9.0 million in revenue for 2019.

In California, Nabis’ planned acquisition of the Desert Springs dispensary is expected to close in September. This is a positive cash-flow asset that had sales of $5.7 million in 2018 with 47 percent gross margins, and it’s on track for a similar performance in 2019. The city of Desert Hot Springs has approved retail expansion from the current 2,076 square feet to almost double that at 3,977 square feet, resulting in a retail space and production and distribution areas that are all under one roof.

Nabis’ Michigan operations include four retail locations, with two more under definitive agreements set to close in Q4 2019. This retail network will be partially supplied by Nabis’ permitted production and cultivation facility, which will be located in Bangor City, where the company has closed on 22 acres of land. The facility has been granted one production license and 10 cultivation licenses.

In Washington, Nabis has purchased extraction and production equipment in Port Townsend. The company plans to expand the facility to include highly specialized equipment, two new extraction lines, an extraction clean room and a lab facility. As part of that deal, the company acquired licensing rights within Washington state for ‘Chong’s Choice’ brand products, a widely recognized brand in the cannabis space.

In addition, Nabis recently strengthened its board with the appointment of Emmanuel Paul as an independent director (http://ibn.fm/Nawb0). Paul currently serves as CEO of IndusCann Research, a company focused on the research and commercialization of medical cannabis in India. Prior to that, he was the founding partner of Spartan Wellness Corporation, a unique, veteran-focused, health care service provider specializing in prescribing medical cannabis, as well as providing education and ongoing care.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NABIF are available in the company’s newsroom at http://ibn.fm/NABIF

• SGMD is ideally positioned as American farmers seek refuge from the low prices and reduced sales created by the ongoing U.S.-China trade war
• A recent USDA survey reported an almost 400 percent increase in hemp acreage in 2019
• The hemp industry generated more than $1 billion in revenues in 2018, and it is projected to grow to $1.9 billion by 2022

Sugarmade Inc. (OTCQB: SGMD), a supplier of hydroponic and cultivation equipment to growers in the booming industrial hemp sector, is well-positioned to fulfill the needs of farmers who are choosing to cultivate hemp. A thriving hemp market offers farmers higher prices and greater sales, as well as an attractive way to offset the impact of the U.S.-China tariff trade war, and an increase in hemp farming has created a need for hydroponic equipment from companies like Sugarmade (http://ibn.fm/l5CeD).

In the wake of the trade war between the United States and China, hemp has become a refuge for American farmers suffering from the resulting lower prices and sinking sales, as detailed in a recent CannabisNewsWire article (http://ibn.fm/BhGYA). The uncertain trade relationship between the two countries has created an especially strong market for companies such as Sugarmade that are suppliers of equipment to hemp cultivators. This is particularly true in the markets seeing the fastest growth in hemp farming, such as Western Kentucky and Tennessee. SGMD is not in the hemp-cultivation business itself, but it has a business model of supporting and supplying hemp-industry cultivators, among others.

As a hydroponic-systems expert and supplier, Sugarmade is benefiting from the growth in hemp cultivation. According to USDA statistics, some 128,320 acres of hemp have been planted this year, compared to only 27,424 last year, marking a nearly 400 percent increase. The growing demand for hemp biomass, especially in Kentucky, is generating significantly higher prices than other crops.

According to Hemp Business Journal, the hemp market in the United States was projected to reach more than $1 billion in 2018, with growth at an estimated 14.4 percent five-year CAGR to $1.9 billion through 2022 (http://ibn.fm/nlqQs). SGMD is poised to become a “strong pick-and-shovel” provider to the hemp industry.

Based in Monrovia, California (a suburb of Los Angeles), Sugarmade is a hydroponics and cultivation supply company that’s committed to supporting the industrial-hemp sector. In addition, SGMD is a product and brand marketing company with numerous operations, such as packaging and paper goods for diverse industries.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR